FDA delay throws off Daiichi Sankyo's timeline for quizartinib

21 April 2023

The US regulator will not be able to complete its review of Daiichi Sankyo’s (TSE: 4568) submission for quizartinib within the expected timeframe.

The Japanese drugmaker is looking to market the FLT3 tyrosine kinase inhibitor for the first-line treatment of adults with FLT3-ITD-positive acute myeloid leukemia (AML).

While the firm had hoped for a decision imminently, the US Food and Drug Administration needs more time to review requested updates to the proposed Risk Evaluation and Mitigation Strategies (REMS).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK